Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival
详细信息 查看全文
- 作者：Marta Rossia ; b ; marta.rossi@marionegri.it" class="auth_mail" title="E-mail the corresponding author ; Greta Cariolib ; Martina Bonifazia ; Alberto Zambellic ; Matteo Franchid ; Lorenzo Mojae ; f ; Antonella Zambond ; Giovanni Corraod ; Carlo La Vecchiab ; Carlo Zocchettig ; Eva Negria
- 关键词：Trastuzumab ; Metastatic breast cancer ; Cardiotoxicity ; Survival
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：52
- 期：Complete
- 页码：41-49
- 全文大小：632 K
文摘
- •
We found 681 trastuzumab metastatic breast cancer users in Lombardy in 2006–2009.
- •
Thirty two (4.7%) women experienced severe cardiac adverse events.
- •
Age was a strong predictor of cardiotoxicity.
- •
The OS was 81.8, 64.0, 50.2, 41.1 and 37.2% at 1, 2, 3, 4 and 5 years, respectively.
- •
Predictors of worse OS were age, brain liver or lung metastasis, and chemotherapy.